Propel Bio Management, LLC Kymera Therapeutics, Inc. Transaction History
Propel Bio Management, LLC
- $154 Billion
- Q2 2024
A detailed history of Propel Bio Management, LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 56,359 shares of KYMR stock, worth $2.43 Million. This represents 1.09% of its overall portfolio holdings.
Number of Shares
56,359
Previous 56,359
-0.0%
Holding current value
$2.43 Million
Previous $2.27 Billion
25.75%
% of portfolio
1.09%
Previous 1.32%
Shares
1 transactions
Others Institutions Holding KYMR
# of Institutions
160Shares Held
63.1MCall Options Held
22.6KPut Options Held
14.4K-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$275 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$258 Million2.38% of portfolio
-
Atlas Venture Life Science Advisors, LLC5.35MShares$230 Million21.28% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$222 Million4.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.82MShares$208 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.36B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...